Perfuze

Perfuze is a private, clinical-stage medical device company targeting the significant unmet need in acute ischemic stroke treatment. Its core technology is the Millipede 088, a next-generation 'superbore' aspiration catheter engineered to achieve higher rates of complete clot ingestion and first-pass reperfusion compared to current stent retriever and small-bore aspiration methods. With its pivotal MARRS IDE trial data presented in 2025, the company is advancing toward regulatory approval and commercialization, aiming to improve patient outcomes in a large and growing global market.

Superbore aspiration catheter technology designed for efficient vessel access and complete clot ingestion in mechanical thrombectomy for acute ischemic stroke.

The competitive landscape is dominated by large medtech players like Medtronic, Stryker, Johnson & Johnson, and Penumbra, who offer integrated thrombectomy systems including stent retrievers and aspiration catheters. Perfuze's Millipede 088 competes directly in the aspiration catheter segment, aiming to differentiate on catheter size (superbore), ease of access, and first-pass efficacy. Its success hinges on proving clinical superiority over existing small-bore aspiration and stent retriever combinations.